-
Tytuł:
-
Real-Life Experience with Aflibercept and Ranibizumab in the Treatment of Newly Diagnosed Neovascular Age-Related Macular Degeneration over 24 Months.
-
Autorzy:
-
Garweg JG; 1 Swiss Eye Institute , Rotkreuz, and Berner Augenklinik am Lindenhofspital, Bern, Switzerland .; 2 University of Bern , Bern, Switzerland .
Gerhardt C; 1 Swiss Eye Institute , Rotkreuz, and Berner Augenklinik am Lindenhofspital, Bern, Switzerland .; 2 University of Bern , Bern, Switzerland .
Kodjikian L; 3 Department of Ophthalmology, Croix-Rousse University Hospital, University Claude Bernard of Lyon 1 , Lyon Cedex, France .
Pfister IB; 1 Swiss Eye Institute , Rotkreuz, and Berner Augenklinik am Lindenhofspital, Bern, Switzerland .; 2 University of Bern , Bern, Switzerland .
-
Źródło:
-
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics [J Ocul Pharmacol Ther] 2017 Sep; Vol. 33 (7), pp. 567-572. Date of Electronic Publication: 2017 May 30.
-
Typ publikacji:
-
Comparative Study; Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Publication: New York, NY : Association For Ocular Pharmacology And Therapeutics
Original Publication: New York, NY : The Association, c1995-
-
MeSH Terms:
-
Angiogenesis Inhibitors/*therapeutic use
Ranibizumab/*therapeutic use
Receptors, Vascular Endothelial Growth Factor/*therapeutic use
Recombinant Fusion Proteins/*therapeutic use
Wet Macular Degeneration/*drug therapy
Aged ; Aged, 80 and over ; Female ; Humans ; Intravitreal Injections ; Male ; Middle Aged ; Retrospective Studies ; Tomography, Optical Coherence ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Visual Acuity ; Wet Macular Degeneration/diagnosis ; Wet Macular Degeneration/physiopathology
-
Contributed Indexing:
-
Keywords: Aflibercept; Ranibizumab; anti-VEGF drugs; intravitreal injections; neovascular age-related macular degeneration; treat-and-extend protocol
-
Substance Nomenclature:
-
0 (Angiogenesis Inhibitors)
0 (Recombinant Fusion Proteins)
0 (VEGFA protein, human)
0 (Vascular Endothelial Growth Factor A)
15C2VL427D (aflibercept)
EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
ZL1R02VT79 (Ranibizumab)
-
Entry Date(s):
-
Date Created: 20170531 Date Completed: 20180427 Latest Revision: 20220409
-
Update Code:
-
20240105
-
DOI:
-
10.1089/jop.2017.0031
-
PMID:
-
28557667
-
Purpose: Comparative data appertaining to the long-term effects of Aflibercept or Ranibizumab in newly diagnosed cases of neovascular age-related macular degeneration (nAMD) over follow-up periods exceeding 12 months in clinical routine are scarce.
Methods: In this retrospective comparative analysis, a case series of patients with treatment-naïve nAMD and requiring anti-vascular endothelial growth factor (VEGF) therapy in a routine clinical setting were treated with either Aflibercept [Afl (n = 106)] or Ranibizumab [Ran (n = 47)]. During the drug-loading phase, 3 monthly injections were administered. Thereafter, a treat-and-extend protocol was pursued for a maximum of 24 months. Ran was administered predominantly in eyes with classical lesions; Afl was administered in all others. The primary outcome parameters included anatomical and functional stability after 24 months.
Results: Patients were comparable regarding age, gender distribution, and lens status. Fewer patients presented with intraretinal fluid in the Afl- than in the Ran group at diagnosis (46.2% vs. 67.4%; P = 0.02), but not after the drug-loading phase. After the drug-loading phase, visual acuity [-4.2 letters (Afl) vs. -4.5 letters (Ran); P = 0.78] and the central foveal thickness remained stable. Linked to the lesion type, the number of scheduled clinical visits during the course of 24 months was higher for the Ran- than for the Afl group [11.9 ± 4.7 visits (Ran) vs. 8.4 ± 3.1 visits (Afl); P = 0.0005]. However, the total number of injections was similar [10.5 ± 2.8 (Ran) vs. 11.7 ± 3.6 (Afl); P = 0.06].
Conclusions: Based on tailoring according to the lesion type in cases of nAMD, the anatomical and the functional outcomes of treatment with either Afl or Ran were comparable for a maximum of 2 years.